What is the significance of fiscal and monetary policy adjustment? Expert: The path of "more active and promising" fiscal policy has been clarified. The Central Economic Work Conference, which closed yesterday, pointed out that a more active fiscal policy and a moderately loose monetary policy should be implemented next year. What kind of signals are released behind these policies? In terms of fiscal policy, the Central Economic Work Conference requested that a more active fiscal policy should be implemented next year, so as to improve the fiscal deficit ratio, increase the issuance of ultra-long-term special government bonds, increase the issuance of special bonds for local governments, optimize the structure of fiscal expenditure, and secure the bottom line of "three guarantees" at the grassroots level. Experts said that these requirements clarified the path of "more active and promising" fiscal policy. Focusing on vigorously boosting consumption, the Central Economic Work Conference requires that special actions to boost consumption should be implemented next year, the basic pension for retirees should be appropriately raised, and the "two new" policies (large-scale equipment renewal and trade-in of consumer goods) should be implemented. (CCTV News)Clown won the TGA Best Indie Game Award.On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)
Wuzhou Spring today bought 101 million yuan and sold 140 million yuan on Shanghai Stock Connect. Wuzhou Spring today traded at a daily limit, with a turnover of 4.335 billion yuan and a turnover rate of 35.76%. After-hours data showed that Ningbo Sangtian Road mat bought 77.1945 million yuan, and Shanghai Stock Connect special seats bought 101 million yuan and sold 140 million yuan.Tesla China will launch advanced intelligent summoning ASS function for vehicles with EAP or FSD. On December 13th, Tesla China official website launched a brand-new vehicle function-Actually Smart Summon. This function is suitable for Tesla vehicles with EAP (enhanced automatic driving assistance function) or FSD (full automatic driving capability). Tesla owners can automatically park the vehicle from the parking space and drive to the owner's side or the location designated by the owner on the mobile phone by operating on the Tesla application of the mobile phone, and the vehicle needs to be kept within the owner's sight during the moving process. It is reported that this function will be pushed to the owner through OTA remote software update function.Today, Shengguang Group bought 170 million yuan and sold 171 million yuan at the daily limit, with a turnover of 6.558 billion yuan and a turnover rate of 3.239%. After-hours data show that the special seats of Shenzhen Stock Connect bought 170 million yuan and sold 171 million yuan.
The yield of China's 30-year national debt "24 Special National Debt 06" fell below 2%, hitting a new low.The turnover of Shanghai and Shenzhen stock markets exceeded 1 trillion yuan for the 53rd consecutive trading day.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.